Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.2308.

Several research analysts have recently weighed in on CMPX shares. Wall Street Zen upgraded Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Compass Point set a $10.00 price objective on Compass Therapeutics in a research note on Monday, October 6th. Cantor Fitzgerald started coverage on Compass Therapeutics in a report on Wednesday. They issued an “overweight” rating for the company. Canaccord Genuity Group started coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $10.00 price target on the stock. Finally, JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday.

Compass Therapeutics Stock Down 0.2%

Compass Therapeutics stock opened at $5.53 on Monday. The company has a fifty day simple moving average of $4.40 and a 200-day simple moving average of $3.43. The firm has a market capitalization of $983.57 million, a price-to-earnings ratio of -12.29 and a beta of 1.43. Compass Therapeutics has a 52-week low of $1.33 and a 52-week high of $5.86.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. On average, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the period. Creative Planning purchased a new stake in Compass Therapeutics in the second quarter valued at $30,000. Strs Ohio acquired a new position in shares of Compass Therapeutics in the 1st quarter valued at $34,000. Apollon Wealth Management LLC purchased a new position in shares of Compass Therapeutics during the 3rd quarter worth $35,000. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Compass Therapeutics during the 3rd quarter worth $37,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.